RecruitingPhase 2NCT06968845
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rein Therapeutics
- Intervention
- LTI-03(drug)
- Enrollment
- 120 target
- Eligibility
- 40 years · All sexes
- Timeline
- 2026 – 2027
Study locations (11)
- UAB Lung Health Center, Birmingham, Alabama, United States
- Paradigm Clinical Research Centers, LLC, San Diego, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Henry Ford Health, Detroit, Michigan, United States
- The Lung Research Center, LLC, Chesterfield, Missouri, United States
- University of Kansas Medical Center, Kansas City, Missouri, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- El Paso Pulmonary Association, El Paso, Texas, United States
- Launceston Respiratory and Sleep Centre, Launceston, Tasmania, Australia
- Salus Aegroti Praktyka Lekarska dr n. med. Grzegorz Gąsior, Sosnowiec, Silesian Voivodeship, Poland
- Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06968845 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGPHASE2NCT07572383Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisPeter Caravan
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- ENROLLING BY INVITATIONNCT06885515Telomeres Length in Israeli Fibrotic ILD PatientsBarzilai Medical Center
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou